Article: Loteprednol, azelastine provide potent arsenal for acute, chronic allergic conjunctivitis

Managing symptoms

Longer-term use proving safe, effective for patients with both seasonal and perennial allergies

Loteprednol etabonate 0.2% (Alrex, Bausch & Lomb) and azelastine hydrochloride 0.05% (Optivar, Muro) are both valuable options for the management of seasonal and perennial allergic conjunctivitis, said Charles Slonim, MD.

Loteprednol offers the unsurpassed efficacy of a corticosteroid for suppressing ocular inflammation and so might be considered the treatment of choice for the acute management of moderate to severe allergic conjunctivitis and even of milder disease that is highly symptomatic, he said.

A retrospective safety analysis under way aims to corroborate ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!